APOC2 and non-small cell lung carcinoma: In non-small cell lung cancer (NSCLC), anti-APOC2 K70 lactylation antibodies neutralize extracellular APOC2, suppressing tumor growth and potentially offering combinational approaches for patients with NSCLC and other APOC2-associated diseases [32].